Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2022

09-10-2021 | Pityriasis Lichenoides Chronica | Original Article

Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA

Authors: Yoshihiro Sakano, Takehiro Noda, Shogo Kobayashi, Akihiro Kitagawa, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hirofumi Akita, Kunihito Gotoh, Tadafumi Asaoka, Masahiro Tanemura, Koji Umeshita, Koshi Mimori, Yuichiro Doki, Hidetoshi Eguchi

Published in: Digestive Diseases and Sciences | Issue 8/2022

Login to get access

Abstract

Background

Combined hepatocellular and cholangiocarcinoma is a rare primary liver cancer with histological features of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Little is known about the prognostic features and molecular mechanism of cHCC-iCCA. Acylphosphatase 1 is a cytosolic enzyme that produces acetic acid from acetyl phosphate and plays an important role in cancer progression.

Aims

We evaluated the clinical significance of ACYP1 expression in cHCC-iCCA, HCC, and iCCA.

Methods

ACYP1 immunohistochemistry was performed in 39 cases diagnosed with cHCC-iCCA. The prognosis was evaluated in three different cohorts (cHCC-iCCA, HCC, and iCCA). The relationships between ACYP1 expression and cell viability, migration, invasiveness, and apoptosis were examined using siRNA methods in vitro. In vivo subcutaneous tumor volumes and cell apoptosis were evaluated after downregulation of ACYP1 expression.

Results

Almost half of the patients with cHCC-iCCA were diagnosed with high ACYP1 expression. In all three cohorts, the cases with high ACYP1 expression had significantly lower overall survival, and high ACYP1 expression was identified as an independent prognostic factor. Downregulation of ACYP1 reduced the proliferative capacity, migration, and invasiveness of both HCC and iCCA cells. Moreover, knockdown of ACYP1 increased the ratio of apoptotic cells and decreased the expression of anti-apoptosis proteins. In vivo tumor growth was significantly inhibited by the transfection of ACYP1 siRNA, and the number of apoptotic cells increased.

Conclusion

High ACYP1 expression could influence the prognosis of cHCC-iCCA, HCC, and iCCA patients. In vitro ACYP1 expression influences the tumor growth and cell viability in both HCC and iCCA by regulating anti-apoptosis proteins.
Literature
1.
go back to reference Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2020;70:313. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2020;70:313.
2.
go back to reference Wang J, Wang F, Kessinger A. Outcome of combined hepatocellular and cholangiocarcinoma of the liver Journal of oncology. 2010;2010. Wang J, Wang F, Kessinger A. Outcome of combined hepatocellular and cholangiocarcinoma of the liver Journal of oncology. 2010;2010.
3.
go back to reference Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Human pathology. 2020;96:48–55.CrossRef Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Human pathology. 2020;96:48–55.CrossRef
4.
go back to reference Kudo M, Matsui O, Izumi N et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma update by the liver cancer study group of japan. Liver Cancer 2014;3:458–468.CrossRef Kudo M, Matsui O, Izumi N et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma update by the liver cancer study group of japan. Liver Cancer 2014;3:458–468.CrossRef
5.
go back to reference Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: The past, the present and the future. Annals of Gastroenterological Surgery 2017;1:5–10.CrossRef Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: The past, the present and the future. Annals of Gastroenterological Surgery 2017;1:5–10.CrossRef
6.
go back to reference Tang D, Nagano H, Nakamura M et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract 2006;10:987–998.CrossRef Tang D, Nagano H, Nakamura M et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract 2006;10:987–998.CrossRef
7.
go back to reference Yoshii Y, Furukawa T, Saga T, Fujibayashi Y. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: overview and application. Cancer Letters 2015;356:211–216.CrossRef Yoshii Y, Furukawa T, Saga T, Fujibayashi Y. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: overview and application. Cancer Letters 2015;356:211–216.CrossRef
8.
go back to reference Bose S, Ramesh V, Locasale JW. Acetate metabolism in physiology, cancer, and beyond. Trends Cell Biol. 2019;29:695–703.CrossRef Bose S, Ramesh V, Locasale JW. Acetate metabolism in physiology, cancer, and beyond. Trends Cell Biol. 2019;29:695–703.CrossRef
9.
go back to reference Stefani M, Taddei N, Ramponi G. Insights into acylphosphatase structure and catalytic mechanism. Cellular and Molecular Life Sciences : CMLS 1997;53:141–151.CrossRef Stefani M, Taddei N, Ramponi G. Insights into acylphosphatase structure and catalytic mechanism. Cellular and Molecular Life Sciences : CMLS 1997;53:141–151.CrossRef
10.
go back to reference Libeer JC, Scharpé SL, Verkerk RM, Deprettere AJ, Schepens PJ. Simultaneous determination of p-aminobenzoic acid, acetyl-p-aminobenzoic acid and p-aminohippuric acid in serum and urine by capillary gas chromatography with use of a nitrogen-phosphorus detector. Clinica Chimica Acta: International Journal of Clinical Chemistry 1981;115:119–123.CrossRef Libeer JC, Scharpé SL, Verkerk RM, Deprettere AJ, Schepens PJ. Simultaneous determination of p-aminobenzoic acid, acetyl-p-aminobenzoic acid and p-aminohippuric acid in serum and urine by capillary gas chromatography with use of a nitrogen-phosphorus detector. Clinica Chimica Acta: International Journal of Clinical Chemistry 1981;115:119–123.CrossRef
11.
go back to reference Riley HD, Macnab J, Farrell TJ, Cohn K. The expression of acylphosphatase is associated with the metastatic phenotype in human colorectal tumors. Carcinogenesis 1997;18:2453–2455.CrossRef Riley HD, Macnab J, Farrell TJ, Cohn K. The expression of acylphosphatase is associated with the metastatic phenotype in human colorectal tumors. Carcinogenesis 1997;18:2453–2455.CrossRef
12.
go back to reference Noda T, Yamamoto H, Takemasa I et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver International: Official Journal of the International Association for the Study of the Liver 2012;32:110–118.CrossRef Noda T, Yamamoto H, Takemasa I et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver International: Official Journal of the International Association for the Study of the Liver 2012;32:110–118.CrossRef
13.
go back to reference Komatsu H, Masuda T, Iguchi T et al. Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Research 2017;37:1083–1090.CrossRef Komatsu H, Masuda T, Iguchi T et al. Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Research 2017;37:1083–1090.CrossRef
14.
go back to reference Kitagawa A, Masuda T, Takahashi J et al. KIF15 Expression in tumor-associated monocytes is a prognostic biomarker in hepatocellular carcinoma. Cancer Genomics & Proteomics 2020;17:141–149.CrossRef Kitagawa A, Masuda T, Takahashi J et al. KIF15 Expression in tumor-associated monocytes is a prognostic biomarker in hepatocellular carcinoma. Cancer Genomics & Proteomics 2020;17:141–149.CrossRef
15.
go back to reference Mikamori M, Yamada D, Eguchi H et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Scientific Reports 2017;7:42339.CrossRef Mikamori M, Yamada D, Eguchi H et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Scientific Reports 2017;7:42339.CrossRef
16.
go back to reference Shinke G, Yamada D, Eguchi H et al. Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer. Cancer Science 2018;109:2520–2531.CrossRef Shinke G, Yamada D, Eguchi H et al. Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer. Cancer Science 2018;109:2520–2531.CrossRef
17.
go back to reference Kondo M, Nagano H, Wada H et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clinical Cancer Research an Official Journal of the American Association for Cancer Research 2005;11:1277–1286.CrossRef Kondo M, Nagano H, Wada H et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clinical Cancer Research an Official Journal of the American Association for Cancer Research 2005;11:1277–1286.CrossRef
18.
go back to reference Yokota Y, Noda T, Okumura Y et al. Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells Cancer Science. 2021. Yokota Y, Noda T, Okumura Y et al. Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells Cancer Science. 2021.
19.
go back to reference Mukai Y, Yamada D, Eguchi H et al. Vitamin D supplementation is a promising therapy for pancreatic ductal adenocarcinoma in conjunction with current chemoradiation therapy. Annals of Surgical Oncology 2018;25:1868–1879.CrossRef Mukai Y, Yamada D, Eguchi H et al. Vitamin D supplementation is a promising therapy for pancreatic ductal adenocarcinoma in conjunction with current chemoradiation therapy. Annals of Surgical Oncology 2018;25:1868–1879.CrossRef
20.
go back to reference Nagaoka S, Yamada D, Eguchi H et al. The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Science 2020;112:347–358.CrossRef Nagaoka S, Yamada D, Eguchi H et al. The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Science 2020;112:347–358.CrossRef
21.
go back to reference Kubo M, Gotoh K, Eguchi H et al. Impact of CD36 on chemoresistance in pancreatic ductal adenocarcinoma. Annals of Surgical Oncology 2020;27:610–619.CrossRef Kubo M, Gotoh K, Eguchi H et al. Impact of CD36 on chemoresistance in pancreatic ductal adenocarcinoma. Annals of Surgical Oncology 2020;27:610–619.CrossRef
22.
go back to reference Matsumoto K, Noda T, Kobayashi S et al. Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma. Cancer Letters 2021;500:29–40.CrossRef Matsumoto K, Noda T, Kobayashi S et al. Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma. Cancer Letters 2021;500:29–40.CrossRef
23.
go back to reference Wakizaka K, Yokoo H, Kamiyama T et al. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma. Hepatol Res 2020;50:258–267.CrossRef Wakizaka K, Yokoo H, Kamiyama T et al. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma. Hepatol Res 2020;50:258–267.CrossRef
24.
go back to reference Xue R, Chen L, Zhang C et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 2019;35:932-947.e938.CrossRef Xue R, Chen L, Zhang C et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 2019;35:932-947.e938.CrossRef
25.
go back to reference Jarnagin WR, Weber S, Tickoo SK et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002;94:2040–2046.CrossRef Jarnagin WR, Weber S, Tickoo SK et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002;94:2040–2046.CrossRef
26.
go back to reference Cazals-Hatem D, Rebouissou S, Bioulac-Sage P et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 2004;41:292–298.CrossRef Cazals-Hatem D, Rebouissou S, Bioulac-Sage P et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 2004;41:292–298.CrossRef
27.
go back to reference Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Human Pathology 1995;26:956–964.CrossRef Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Human Pathology 1995;26:956–964.CrossRef
28.
go back to reference Yano Y, Yamamoto J, Kosuge T et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Japanese Journal of Clinical Oncology 2003;33:283–287.CrossRef Yano Y, Yamamoto J, Kosuge T et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Japanese Journal of Clinical Oncology 2003;33:283–287.CrossRef
29.
go back to reference Delic D, Wunderlich F, Al-Quraishy S, Abdel-Baki AS, Dkhil MA, Araúzo-Bravo MJ. Vaccination accelerates hepatic erythroblastosis induced by blood-stage malaria. Malaria Journal 2020;19:49.CrossRef Delic D, Wunderlich F, Al-Quraishy S, Abdel-Baki AS, Dkhil MA, Araúzo-Bravo MJ. Vaccination accelerates hepatic erythroblastosis induced by blood-stage malaria. Malaria Journal 2020;19:49.CrossRef
30.
go back to reference Szklarczyk D, Gable AL, Lyon D et al. STRING v11 protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research 2019;47:D607-d613.CrossRef Szklarczyk D, Gable AL, Lyon D et al. STRING v11 protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research 2019;47:D607-d613.CrossRef
31.
go back to reference Wen F, Huang J, Lu X et al. Identification and prognostic value of metabolism-related genes in gastric cancer. Aging 2020;12:17647–17661.CrossRef Wen F, Huang J, Lu X et al. Identification and prognostic value of metabolism-related genes in gastric cancer. Aging 2020;12:17647–17661.CrossRef
32.
go back to reference Cui L, Xue H, Wen Z, Lu Z, Liu Y, Zhang Y. Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. Aging 2020;12:22199–22219.CrossRef Cui L, Xue H, Wen Z, Lu Z, Liu Y, Zhang Y. Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. Aging 2020;12:22199–22219.CrossRef
33.
go back to reference Cao J, Wei J, Yang P et al. Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance. Molecular Cancer 2018;17:121.CrossRef Cao J, Wei J, Yang P et al. Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance. Molecular Cancer 2018;17:121.CrossRef
34.
go back to reference Izadi S, Moslehi A, Kheiry H et al. Codelivery of HIF-1α siRNA and dinaciclib by carboxylated graphene oxide-trimethyl chitosan-hyaluronate nanoparticles significantly suppresses cancer cell progression. Pharmaceutical Research 2020;37:196.CrossRef Izadi S, Moslehi A, Kheiry H et al. Codelivery of HIF-1α siRNA and dinaciclib by carboxylated graphene oxide-trimethyl chitosan-hyaluronate nanoparticles significantly suppresses cancer cell progression. Pharmaceutical Research 2020;37:196.CrossRef
35.
go back to reference Maurer U, Preiss F, Brauns-Schubert P, Schlicher L, Charvet C. GSK-3 - at the crossroads of cell death and survival. Journal of Cell Science 2014;127:1369–1378.CrossRef Maurer U, Preiss F, Brauns-Schubert P, Schlicher L, Charvet C. GSK-3 - at the crossroads of cell death and survival. Journal of Cell Science 2014;127:1369–1378.CrossRef
36.
go back to reference Wakizaka K, Yokoo H, Kamiyama T et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. Journal of Gastroenterology and Hepatology 2019;34:1074–1080.CrossRef Wakizaka K, Yokoo H, Kamiyama T et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. Journal of Gastroenterology and Hepatology 2019;34:1074–1080.CrossRef
37.
go back to reference Wang J, Li E, Yang H et al. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. World Journal of Surgical Oncology 2019;17:43.CrossRef Wang J, Li E, Yang H et al. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. World Journal of Surgical Oncology 2019;17:43.CrossRef
38.
go back to reference Lee JH, Chung GE, Yu SJ et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. Journal of Clinical Gastroenterology 2011;45:69–75.CrossRef Lee JH, Chung GE, Yu SJ et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. Journal of Clinical Gastroenterology 2011;45:69–75.CrossRef
39.
go back to reference Jung DH, Hwang S, Kim KH et al. Clinicopathological features and post-resection prognosis of double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World Journal of Surgery 2017;41:825–834.CrossRef Jung DH, Hwang S, Kim KH et al. Clinicopathological features and post-resection prognosis of double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World Journal of Surgery 2017;41:825–834.CrossRef
40.
go back to reference Ishii T, Ito T, Sumiyoshi S et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World Journal of Surgical Oncology 2020;18:319.CrossRef Ishii T, Ito T, Sumiyoshi S et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World Journal of Surgical Oncology 2020;18:319.CrossRef
Metadata
Title
Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA
Authors
Yoshihiro Sakano
Takehiro Noda
Shogo Kobayashi
Akihiro Kitagawa
Yoshifumi Iwagami
Daisaku Yamada
Yoshito Tomimaru
Hirofumi Akita
Kunihito Gotoh
Tadafumi Asaoka
Masahiro Tanemura
Koji Umeshita
Koshi Mimori
Yuichiro Doki
Hidetoshi Eguchi
Publication date
09-10-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07266-x

Other articles of this Issue 8/2022

Digestive Diseases and Sciences 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.